|
Claude Quesnelle, Ph. D.
Director of Chemistry at Eternity Bioscience Inc., Cranbury, New Jersey Claude Quesnelle earned his Ph.D. in Synthetic Organic Chemistry at the University of Waterloo, Ontario Canada, in 1996 under the guidance of Professor Victor Snieckus. His doctoral thesis was trifold: Investigated the tert-butyl sulfoxide moiety as a Directed Metalation Group (DMG) used in the Directed ortho Metalation (DoM) reaction; Developed the nickel-catalyzed variants of Kumada–Tamao–Corriu and Negishi cross coupling reactions with organotriflates, and comparing these to the powerful Suzuki reaction; And lastly, laid the ground work for the total synthesis of Sterigmatocystin, an aflatoxin biosynthetic precursor, via a radical-induced cyclization. Claude then undertook his Post-Doctoral studies at the Colorado State University in the group of Professor Robert M. Williams studying the biosynthesis of paclitaxel. After starting his career at Cadus Pharmaceuticals, Claude joined Bristol-Myers Squibb in 1999 at their Candiac, Quebec Canada research center then later relocated to their Princeton, NJ site. Over his 21-year career at BMS, Claude undertook research in various therapeutic areas including antibacterial, antifungal, immunology, oncology, I-O and fibrosis gaining experience with a variety of targets including kinases, phosphodiesterases, cell signaling pathways and checkpoint inhibitors. Importantly, his experience runs the gamut from High Throughput Screening hit validation/lead generation through lead optimization to, and with a proven track history of integral contributions to teams that delivered, clinical candidates including their conception. Claude joined EBI in October 2020. |